Regulatory Roundup: FDA Publishes CDER Presentation, and more. - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Publishes CDER Presentation, and more.

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has published on its website a presentation given by Center for Drug Evaluation and Research (CDER) Director Janet Woodcock on Dec. 9. 2010. The presentation provides a thorough overview of CDER efforts, including the Sentinel initiative, new molecular entity approvals, REMS, and more.

FDA issued on Jan. 7, 2011 another warning about criminals posing as agency officials and other law enforcement personnel as part of a continued international extortion scam. In most cases, criminals call victims who have purchased drugs over the Internet and say they are being charged a fine of $100 to $250,000. Victims are asked to wire the money, and if they do not do so, are often threatened. See the agency’s list of questions and answers about the scam.

The agency has announced a CDER Forum for International Drug Regulatory Authorities to take place April 4–8, 2011, in College Park, MD. The annual forums provide an overview of CDER offices. The 2011 forum will also focus on a product review case study of Etravirine, which is used to treat HIV, to demonstrate how CDER product reviews work. Registration information and requests should be sent to


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here